Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ImmuFact IMP321: Interim Phase I/II data

In an open-label, dose-escalation, French Phase I/II trial, initial data from 8

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE